Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6775753 | 0.92 | KMT2A (0.41) | KMT2ANOTUMLMNAMEN1HTR2A | |
| SCHEMBL7099398 | 0.88 | KMT2A (0.40) | KMT2ACNR2XIAPBIRC2NOTUM | |
| SCHEMBL7026550 | 0.84 | MAPT (0.43) | KMT2ANOTUMLMNAMEN1ALDH1A1 | |
| SCHEMBL7613843 | 0.83 | KMT2A (0.39) | KMT2ACNR2XIAPBIRC2NOTUM | |
| SCHEMBL7101845 | 0.81 | HDAC8 (0.35) | KMT2ACNR2XIAPBIRC2NOTUM | |
| SCHEMBL7743748 | 0.78 | ALDH1A1 (0.39) | CNR2LMNAHTR2AHTR2CALDH1A1 | |
| SCHEMBL7101931 | 0.74 | KMT2A (0.41) | KMT2ANOTUMLMNAHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6774822 | 0.73 | CNR2 (0.37) | KMT2ACNR2XIAPBIRC2NOTUM | |
| SCHEMBL9393577 | 0.69 | CNR2 (0.52) | CNR2XIAPBIRC2NOTUMHTR2A | |
| SCHEMBL6770333 | 0.68 | GPBAR1 (0.49) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1041986-A4 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1041986-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999018962-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-22 | — | — | WO | claimed |
| US-6774263-B1 | N-(2-CHLORO-5-METHYLTHIOPHENYL)-N'-(3-METHYLSULFINYLPHENYL)-N' -METHYLGUANIDINE; NEURODEGENERATIVE DISORDER TREATMENT | CAMBRIDGE NEUROSCIENCE, INC. | 2004-08-10 | — | — | US | disclosed |
| US-6774263-B1 | N-(2-CHLORO-5-METHYLTHIOPHENYL)-N'-(3-METHYLSULFINYLPHENYL)-N' -METHYLGUANIDINE; NEURODEGENERATIVE DISORDER TREATMENT | CAMBRIDGE NEUROSCIENCE, INC. | 2004-08-10 | — | — | US | disclosed |
| EP-1041986-A4 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1041986-A4 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1041986-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1041986-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999018962-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1999018962-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-22 | — | — | WO | disclosed |